What it takes for a drug to be sold over the counter

A third route onto a shelf

Two paths are familiar. A drug can be approved individually, product by product. A supplement can be sold without approval under a different statute and a different rulebook.

There is a third, and it explains most of what sits in a pharmacy aisle. A product can be sold over the counter without its own approval if it matches a published set of conditions.

Part 330 of title 21 is where those conditions live. Its heading names the standard: over-the-counter human drugs which are generally recognized as safe and effective and not misbranded.

That phrase is a legal status, not a compliment. It means the product falls inside a description somebody already wrote down.

The conditions are cumulative, and the penalty is stated first

Section 330.1 opens by defining the arrangement and its failure mode in the same breath.

A listed over-the-counter drug "is generally recognized as safe and effective and is not misbranded if it meets each of the conditions contained in this part." It must equally meet "each of the conditions contained in any applicable monograph."

Then the consequence: "Any product which fails to conform to each of the conditions contained in this part and in an applicable monograph is liable to regulatory action."

The word each is doing a lot of work in both sentences. This is not a scoring system with a passing grade. Missing one condition removes the status entirely.

What the conditions actually are

They read like a checklist of everything else in the drug system, pulled into one place.

The product "is manufactured in compliance with current good manufacturing practices" under the drug manufacturing regulations.

The establishment where it is made "is registered, and the drug product is listed" under the registration rules. The number assigned there is "requested but not required" to appear on the labels.

The product is labeled in compliance with the statute and the labeling regulations, "including the format and content requirements" of the over-the-counter labeling rule.

It "contains only suitable inactive ingredients which are safe in the amounts administered." Those ingredients must not interfere with the effectiveness of the preparation, or with the tests used to check its professed standards.

And its container and container components meet the drug manufacturing rules on containers.

The advertising condition, which is unusual

One item in the list is not about the product at all.

Paragraph (d) requires that "The advertising for the product prescribes, recommends, or suggests its use only under the conditions stated in the labeling."

That is a labeling regulation reaching outward into marketing, and its effect is worth spelling out. Promoting a monograph product for something outside its labeled conditions is not merely an advertising problem.

Because the conditions are cumulative, failing this one takes the product outside general recognition. The status that allowed it to be sold without an individual approval depends in part on how it is advertised.

The words are prescribed, sometimes exactly

Paragraph (c)(2) governs what the label may say a product is for, and it is narrow.

The Uses section must contain the labeling describing the indications "that have been established in an applicable OTC drug monograph." The alternative is "alternative truthful and nonmisleading statements describing only those indications for use that have been established in an applicable monograph."

Other labeling must be "stated in the exact language where exact language has been established and identified by quotation marks in an applicable OTC drug monograph or by regulation."

There are two general warnings the section writes out itself. All such labeling must carry a keep out of reach of children warning. A second statement covers what to do in case of overdose or accidental swallowing, phrased differently for oral, topical, rectal and vaginal products.

Paragraph (i) then supplies a long list of interchangeable phrases, so that plainer wording can be used without altering established meaning. Doctor or physician. Discard or throw away. Immediately or right away. The list runs to dozens of pairs.

That list is a plain-language provision hiding inside a regulation, and it is the clearest signal of what the whole part is optimizing for.

How a monograph gets written

Section 330.10 sets out the process, and its shape explains why the resulting documents are so specific.

Advisory review panels of qualified experts are appointed "to evaluate the safety and effectiveness of OTC drugs, to review OTC drug labeling," and to advise on establishing monographs. One panel is established for each designated category, and "every OTC drug category will be considered by a panel."

The agency publishes a notice requesting interested persons to submit published and unpublished data. The required submission format is printed in the regulation itself, and it is a demanding structure. Animal safety data, human safety data and efficacy data are each split between individual active components, combinations of those components, and the finished drug product. Each of those is split again between controlled studies and partially controlled or uncontrolled ones.

It also asks for a rationale. Where there is an absence of controlled studies in the material submitted, "an explanation as to why such studies are not considered necessary must be included."

And it asks for a compendial standard for the active ingredient, or a proposed one. The submission must show that the standard is consistent with the ingredient used in the studies and with what is actually marketed. Those compendial texts are copyrighted and are not reproduced here.

What this tells a peptide buyer

Mostly it tells you what a real over-the-counter status requires, which makes an unsupported claim of one easier to spot.

A product is generally recognized as safe and effective only by matching an existing monograph, condition for condition, including manufacturing, registration and listing, container, inactive ingredients, prescribed wording, and advertising.

There is no self-certification step in that list. A company cannot place itself in this category by concluding that its ingredient qualifies.

Nothing on this page says that any peptide is, could be, or should be an over-the-counter monograph drug. That is a question decided through the process section 330.10 describes, and it is not answered here.

This is a summary of a regulation. It names no seller, assesses nobody's compliance, and is not legal or medical advice.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Title 21 Code of Federal Regulations section 330.1, General conditions for general recognition as safe, effective and not misbranded — Electronic Code of Federal Regulations, Office of the Federal Register, July 2023
2. Title 21 Code of Federal Regulations section 330.10, Procedures for classifying OTC drugs as generally recognized as safe and effective and not misbranded, and for establishing monographs — Electronic Code of Federal Regulations, Office of the Federal Register, July 2023